Get the Stockscreener App
4.18
1.65%
-0.07
After Hours:
3.88
-0.30
-7.18%
Reshape Lifesciences Inc stock is traded at $4.18, with a volume of 216.10K.
It is down -1.65% in the last 24 hours and down -62.43% over the past month.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.
See More
Previous Close:
$4.25
Open:
$4.2
24h Volume:
216.10K
Relative Volume:
0.14
Market Cap:
$3.62M
Revenue:
$9.81M
Net Income/Loss:
$-26.16M
P/E Ratio:
-0.1078
EPS:
-38.77
Net Cash Flow:
$-17.45M
1W Performance:
-14.87%
1M Performance:
-62.43%
6M Performance:
-96.63%
1Y Performance:
-98.77%
1-Day Range:
$4.11
$4.3154
1-Week Range:
$4.03
$8.29
52-Week Range:
$4.03
$414.99
Reshape Lifesciences Inc Stock (RSLS) Company Profile
Name
Reshape Lifesciences Inc
Sector
Industry
Phone
949-429-6680
Address
1001 CALLE AMANECER, SAN CLEMENTE
Compare RSLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RSLS
Reshape Lifesciences Inc
|
4.18 | 3.62M | 9.81M | -26.16M | -17.45M | -38.77 |
|
ABT
Abbott Laboratories
|
133.58 | 232.41B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.09 | 155.73B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
383.89 | 146.23B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
87.44 | 106.37B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.52 | 45.88B | 5.54B | 4.18B | 623.10M | 7.00 |
Reshape Lifesciences Inc Stock (RSLS) Latest News
SEC Form 424B3 filed by ReShape Lifesciences Inc. - Quantisnow
ReShape Lifesciences achieves EU and UK medical device certification By Investing.com - Investing.com South Africa
ReShape Lifesciences And Kiora Pharma Impress Investors, Dollar General Uplifts Outlook - Finimize
Why ReShape Lifesciences Stock Is Soaring Today: Key Drivers Behind Weight-Loss Company's Surge - Benzinga
ReShape Lifesciences Receives EU Certification for Product Portfolio; Shares Jump - marketscreener.com
ReShape Lifesciences Stock Soars On Regulatory Certification For Medical Devices In EU, UK: Retail Eyes Fair Valuation - Asianet Newsable
ReShape Lifesciences Stock Soars On Regulatory Certification For Medical Devices In EU, UK: Retail Eyes Fair Valuation By Stocktwits - Investing.com India
ReShape Lifesciences (RSLS) Stock Skyrockets Over 62% in Morning Trading Frenzy - Daily Chhattisgarh News
ReShape Lifesciences achieves EU and UK medical device certification - Investing.com India
ReShape Lifesciences (RSLS) Achieves Key European and UK Certifications | RSLS Stock News - GuruFocus
ReShape Lifesciences Achieves EU MDR and UKCA Certification for Medical Devices, Enhancing Patient Safety and Market Access in Europe - Nasdaq
ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio - GlobeNewswire
ReShape Lifesciences Beats 2027 Deadline: Gains Crucial EU MDR Certification While Others Still Wait - Stock Titan
RSLS stock touches 52-week low at $4.03 amid market challenges By Investing.com - Investing.com South Africa
RSLS stock touches 52-week low at $4.03 amid market challenges - Investing.com India
ReShape Lifesciences Faces Nasdaq Delisting Notice - TipRanks
ReShape Lifesciences Announces Equity Distribution Agreement - TipRanks
ReShape Lifesciences announces merger progress By Investing.com - Investing.com South Africa
ReShape Lifesciences Announces Merger with Vyome Therapeutics - TipRanks
ReShape Lifesciences announces merger progress - Investing.com
ReShape Lifesciences (NASDAQ:RSLS) Raised to Hold at Wall Street Zen - Defense World
ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update - GlobeNewswire
RSLS stock touches 52-week low at $5.5 amid market challenges - Investing.com
ReShape Lifesciences reports Q1 EPS $18.98 vs. ($135.37) last year - TipRanks
ReShape Lifesciences (RSLS) Reports Q1 Revenue Drop and Highlights Strategic Advances | RSLS Stock News - GuruFocus
ReShape Lifesciences Inc. Reports First Quarter 2025 Financial Results and Strategic Updates - Nasdaq
ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides ... - Bluefield Daily Telegraph
ReShape Reports 43% Revenue Drop While Advancing Merger Deal and Securing Key Patents - Stock Titan
ReShape Lifesciences Inc. SEC 10-Q Report - TradingView
ReShape Lifesciences Delays 10-Q Filing - TipRanks
Orla Mining, ReShape Lifesciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Stocktwits Spotlight: NRx, CVS, ReShape Lead Weekly Jump In Health Care Stock Chatter - MSN
Reshape Lifesciences Inc Files For Mixed Shelf Offering Of Up To $50 MillionSEC Filing - marketscreener.com
ReShape Lifesciences Announces Reverse Stock Split - TipRanks
ReShape Lifesciences announces 1-for-25 reverse stock split By Investing.com - Investing.com Canada
ReShape Lifesciences (RSLS) Announces 1-for-25 Reverse Stock Spl - GuruFocus
ReShape Lifesciences announces 1-for-25 reverse stock split - Investing.com Australia
ReShape Lifesciences Announces 1-for-25 Reverse Stock Split - The Manila Times
ReShape Lifesciences Inc. Announces 1-for-25 Reverse Stock Split Effective May 9, 2025 - Nasdaq
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The MergerALBT, NDOI, DNB, RSLS - The Malaysian Reserve
ReShape Lifesciences (RSLS) Secures Patent for Innovative Intrag - GuruFocus
RSLSReshape Lifesciences Inc. Latest Stock News & Market Updates - Stock Titan
ReShape Lifesciences (RSLS) Showcases Promising Diabetes Device at Neuromodulation Event | RSLS Stock News - GuruFocus
ReShape Lifesciences® Unveils Innovative Diabetes Neuromodulation Device Demonstrating Safe Glucose Modulation at Minnesota Neuromodulation Symposium - Nasdaq
ReShape Lifesciences® Presents Pre-clinical Data on Its - GlobeNewswire
Breakthrough Diabetes Treatment: New Neuromodulation Device Eliminates Need for Insulin Injections - Stock Titan
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – ALBT, NDOI, DNB, RSLS - GlobeNewswire Inc.
The Psychology of ReShape Lifesciences Inc Inc. (RSLS) Price Performance: Understanding Market Sentiment - investchronicle.com
Reshape Lifesciences Inc Stock (RSLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.56%
1.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):